APRE (STOCKS)
Aprea Therapeutics, Inc. Common stock
$0.698600
+0.012500 (+1.82%)
Prev close: $0.686100
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Oren Gilad
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $8.93M
- Employees
- 8
- P/E (TTM)
- -0.44
- P/B (TTM)
- 0.20
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
4
Strong Buy
5
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.22 | $-0.23 | +0.0146 | +6.22% |
|
Dec 2025 (Q4)
|
$-0.32 | $-0.40 | +0.0778 | +19.56% |
|
Sep 2025 (Q3)
|
$-0.47 | $-0.35 | -0.1247 | -36.11% |
|
Jun 2025 (Q2)
|
$-0.53 | $-0.76 | +0.2299 | +30.25% |
Financial Statements
| Revenues | $123.30K |
| Operating Expenses | $12.70M |
| Operating Income/Loss | -$12.58M |
| Income/Loss From Continuing Operations After Tax | -$11.95M |
| Income/Loss From Continuing Operations Before Tax | -$11.95M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$11.95M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$11.95M |
| Net Income/Loss Available To Common Stockholders, Basic | -$11.95M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.50 |
| Diluted Earnings Per Share | -$1.50 |
| Basic Average Shares | 27,529,004 |
| Diluted Average Shares | 27,529,004 |
| Assets | $47.61M |
| Current Assets | $47.25M |
| Noncurrent Assets | $366.95K |
| Fixed Assets | $54.38K |
| Other Non-current Assets | $312.57K |
| Liabilities | $6.02M |
| Current Liabilities | $5.30M |
| Accounts Payable | $2.94M |
| Wages | $573.40K |
| Other Current Liabilities | $1.78M |
| Noncurrent Liabilities | $727.36K |
| Equity | $41.59M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $41.59M |
| Liabilities And Equity | $47.61M |
| Net Cash Flow From Operating Activities | -$12.02M |
| Net Cash Flow From Operating Activities, Continuing | -$12.02M |
| Net Cash Flow From Investing Activities | -$27.19M |
| Net Cash Flow From Investing Activities, Continuing | -$27.19M |
| Net Cash Flow From Financing Activities | $39.21M |
| Net Cash Flow From Financing Activities, Continuing | $39.21M |
| Net Cash Flow | $0.00 |
| Net Cash Flow, Continuing | $0.00 |
| Comprehensive Income/Loss | -$11.95M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$11.95M |
| Other Comprehensive Income/Loss | -$2.97M |